NEW YORK (GenomeWeb News) – Medicyte and Reinnervate today announced a collaboration to combine their technologies, bringing a next generation of cell-based assays to the biopharma and academic research markets.

The partnership brings together Medicyte's upcyte technology and Reinnervate's Alvetex Scaffold technologies. Upcyte are genetically engineered "upregulated" primary cells, and according to Medicyte, data suggests that upcyte hepatocytes combine the benefits of quantity — up to 2,000 vials per donor can be generated — and the quality of primary hepatocytes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.